Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Lancet Oncol. 2022 Mar;23(3):416-427. doi: 10.1016/S1470-2045(22)00019-5. Epub 2022 Feb 10.
Lancet Oncol. 2022.
PMID: 35151415
Clinical Trial.
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Dimopoulos MA, Leleu X, Moreau P, Richardson PG, Liberati AM, Harrison SJ, Miles Prince H, Ocio EM, Assadourian S, Campana F, Malinge L, Sémiond D, van de Velde H, Yong K.
Dimopoulos MA, et al. Among authors: malinge l.
Leukemia. 2021 Feb;35(2):562-572. doi: 10.1038/s41375-020-0868-z. Epub 2020 May 23.
Leukemia. 2021.
PMID: 32444867
Free PMC article.
Clinical Trial.
Item in Clipboard
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
Capra M, Martin T, Moreau P, Baker R, Pour L, Min CK, Leleu X, Mohty M, Segura MR, Turgut M, LeBlanc R, Risse ML, Malinge L, Schwab S, Dimopoulos M.
Capra M, et al. Among authors: malinge l.
Haematologica. 2022 Jun 1;107(6):1397-1409. doi: 10.3324/haematol.2021.279229.
Haematologica. 2022.
PMID: 34647444
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite